Treatment > Chemoresistance · Temozolomide Investigations


Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 579. (Laboratory Investigation)


Meeting Abstract

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

Takao Kanzawa, Hideaki Ito, Yasuko Kondo, Seiji Kondo

The University of Texas M. D. Anderson Cancer Center, Houston, TX. E-mail: seikondo@mdanderson.org

Autophagy is originally named as a process of protein recycling. 
It begins with sequestering cytoplasmic organelles in a membrane vacuole called autophagosome. 
Autophagosomes then fuse with lysosomes, where the materials inside are degraded and recycled. 
To date, however, little is known about the role of autophagy in cancer therapy. 
In this study, we present that temozolomide (TMZ), a new alkylating agent, inhibited the viability of malignant glioma cells in a dose-dependent manner and induced G2/M arrest. 
At a clinically achievable dose (100 μM), TMZ induced autophagy, but not apoptosis in malignant glioma cells. 
After the treatment with TMZ, microtubule-associated protein light chain 3 (LC3), a mammalian homologue of Apg8p/Aut7p essential for amino acid starvation-induced autophagy in yeast, was recruited on autophagosome membranes. 
When autophagy was prevented at an early stage by 3-methyladenine, a phosphatidylinositol 3-phosphate kinase inhibitor, not only the characteristic pattern of LC3 localization, but also the anti-tumor effect of TMZ was suppressed. 
On the other hand, bafilomycin A1, a specific inhibitor of vacuolar type H+-ATPase, that prevents autophagy at a late stage by inhibiting fusion between autophagosomes and lysosomes, sensitized tumor cells to TMZ by inducing apoptosis through activation of caspase-3 with mitochondrial and lysosomal membrane permeabilization, while LC3 localization pattern stayed the same. 
These results indicate that TMZ induces autophagy in malignant glioma cells. 
Application of an autophagy inhibitor that works after the association of LC3 with autophagosome membrane, such as bafilomycin A1, is expected to enhance the cytotoxicity of TMZ for malignant gliomas.

Copyright © 2004 American Association for Cancer Research. All rights reserved.

Source: http://aacr04.agora.com/planner/displayabstract.asp?presentationid=283



 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
|
Children's Corner | E-mail Alerts | Journals | Newsletter | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP